Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies

被引:69
作者
Greenblatt, DJ
von Moltke, LL
Perloff, ES
Luo, Y
Harmatz, JS
Zinny, MA
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA
[3] ProMedica Clin Res Ctr, Boston, MA USA
关键词
D O I
10.1016/j.clpt.2005.09.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Recent anecdotal, unvalidated case reports have suggested potentiation of warfarin-induced anticoagulation by cranberry juice, possibly through inhibition of human cytochrome P450 (CYP) 2C9, the enzyme responsible for the clearance of the active S-enantiomer of warfarin. To address this question, the effect of cranberry juice and other beverages on CYP2C9 activity was evaluated in vitro and in vivo. Methods: The effects of 4 beverages on CYP2C9 activity were studied in human liver microsomes, by use of flurbiprofen hydroxylation as the index reaction. In a clinical study 14 healthy volunteers received 100 mg flurbiprofen on 5 occasions in a crossover fashion, with at least 1 week separating the 5 trials. Flurbiprofen was preceded in random sequence by the following: (1) cranberry juice placebo (8 oz), (2) cranberry juice (8 oz), (3) brewed tea (8 oz), (4) grape juice (8 oz), and (5) fluconazole, a CYP2C9 inhibitor serving as a positive control, with 8 oz of water. Results: Flubiprofen hydroxylation in vitro was reduced to 11% +/- 8% of control by 2.5% (vol/vol) brewed tea, to 10% +/- 7% of control by grape juice, to 56% +/- 16% of control by cranberry juice, to 85% +/- 5% of control by cranberry juice placebo, and to 21% +/- 6% of control by the index inhibitor sulfaphenazole (2.5 mu mol/L) (P < .01 for all comparisons versus control). Flurbiprofen clearance (29-33 mL/min) and elimination half-life (3.3-3.4 hours) did not differ significantly among trials 1, 2, 3, and 4. However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P < .05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P < .05). Formation of 4-hydroxyflurbiprofen was correspondingly reduced by fluconazole (P < .05). Conclusions: Although grape juice and tea impaired CYP2C9 activity in vitro, none of the 3 beverages altered CYP2C9-mediated clearance of flurbiprofen in humans, making a pharmacokinetic interaction with warfarin highly unlikely.
引用
收藏
页码:125 / 133
页数:9
相关论文
共 60 条
[11]   CLINICAL PHARMACOKINETICS OF FLUCONAZOLE [J].
DEBRUYNE, D ;
RYCKELYNCK, JP .
CLINICAL PHARMACOKINETICS, 1993, 24 (01) :10-27
[12]  
Freedman JE, 2001, CIRCULATION, V103, P2792, DOI 10.1161/01.CIR.103.23.2792
[13]  
Frye RF, 2000, CLIN PHARMACOL THER, V67, P109
[14]   Drug interactions with grapefruit juice - Extent, probable mechanism and clinical relevance [J].
Fuhr, U .
DRUG SAFETY, 1998, 18 (04) :251-272
[15]   Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine [J].
Giancarlo, GM ;
Venkatakrishnan, K ;
Granda, BW ;
von Moltke, LL ;
Greenblatt, DJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :31-36
[16]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[17]  
Grant P, 2004, J HEART VALVE DIS, V13, P25
[18]   Effect of Ginkgo on CYP2C9: In vitro and in vivo studies. [J].
Greenblatt, DJ ;
von Moltke, LL ;
Perloff, ES ;
Luo, Y ;
Harmatz, JS ;
Bedir, E ;
Khan, IA ;
Goldman, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) :P48-P48
[19]   Interaction of warfarin with drugs, natural substances, and foods [J].
Greenblatt, DJ ;
von Moltke, LL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :127-132
[20]   Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole [J].
Greenblatt, DJ ;
von Moltke, LL ;
Harmatz, JS ;
Mertzanis, P ;
Graf, JA ;
Durol, ALB ;
Counihan, M ;
Roth-Schechter, B ;
Shader, RI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) :661-671